Myelotoxicity evaluation of 2 potential anticancer compounds using murine and human in vitro CFU-GM assays (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Myelotoxicity evaluation of 2 potential anticancer compounds using murine and human in vitro CFU-GM assays (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A2281 1993. Unique Identifier : AIDSLINE ICDB/93693232
May RD; Murphy MJ Jr; Erickson-Miller CL; Parchment RE; Tomaszewski JE; Osborn BL; Page JG; Southern Res. Inst., Birmingham, AL 35255-5305

Abstract: An important aspect in the preclinical development of an anticancer or anti-HIV drug is the evaluation of its potential myelotoxicity. Two investigational drugs were assessed for their toxicity to murine and human bone marrow (BM) using in vitro CFU-GM assays. These included bizelesin (U77,779; NSC-615291), and NSC-630176D. BM cells were exposed to drug concentrations of 10 pM to 10 uM either for 1 hr or continuously. IC50 values for bizelesin were as follows: (1) mouse--1.3 uM at 1 hr, less than 10 pM continuous; (2) human--less than 100 pM at 1 hr, less than 10 pM continuous. IC50 values for NSC-630176D were as follows: (1) mouse--5 uM at 1 hr, 2 nM continuous; (2) human--0.6 uM at 1 hr, 1.2 nM continuous. These data may be useful in predicting BM toxicity upon in vivo administration of these severely myelotoxic drugs.

Keywords: Animal Antineoplastic Agents/*TOXICITY Bone Marrow/*DRUG EFFECTS Cell Line *Colony-Forming Units Assay Dose-Response Relationship, Drug Granulocytes/*DRUG EFFECTS Human Macrophages/*DRUG EFFECTS Mice *Tumor Stem Cell Assay ABSTRACT
930830
M9380829

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .